Compile Data Set for Download or QSAR
Report error Found 31 Enz. Inhib. hit(s) with all data for entry = 165
Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199539((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50: 0.462nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199092(US9670229, 6 | (1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1...)
Affinity DataIC50: 0.510nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199498(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.600nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199098(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.620nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199522((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 0.650nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199485(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.650nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199504(5-fluoro-n-((1r,5s,7s)-9-methyl-3-oxa-9- azabicycl...)
Affinity DataIC50: 0.662nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199484((1r,5s,7s)-9-methyl-d3-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.680nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199096(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.690nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199501(5-fluoro-n-((1r,5s,7s)-9-methyl-3-oxa-9- azabicycl...)
Affinity DataIC50: 0.720nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199541((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50: 0.745nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199513((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 0.75nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199482((1r,5s,7s)-9-methyl-d3-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.810nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199500(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.882nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199091((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 0.950nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199094((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 0.960nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199524((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 1.01nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199092(US9670229, 6 | (1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1...)
Affinity DataIC50: 1.10nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199521((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 1.10nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199518((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 1.20nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199503(5-fluoro-n-((1r,5s,7s)-9-methyl-3-oxa-9- azabicycl...)
Affinity DataIC50: 1.34nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199544(3-(3-(((1r,5s,7s)-9-methyl- 3-oxa-9-azabicyclo[3.3...)
Affinity DataIC50: 1.36nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199527((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 1.39nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199533((1r,5s,7s)-9-methyl-3-oxa-9- azabicyclo[3.3.1]nona...)
Affinity DataIC50: 1.44nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199520((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 1.5nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199518((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 2.01nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199538((1r,5s,7s)-9-methyl-3-oxa-9- azabicyclo[3.3.1]nona...)
Affinity DataIC50: 2.04nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199512((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 2.5nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199110((1r,5s,7s)-9-methyl-d3-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 2.86nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199519((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 3.68nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199542((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50: 1.00E+3nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In DepthDetails
US Patent